Bhagiradha Chemicals & Industries (BCIL) is betting big on a scaled-up manufacturing future, with its subsidiary Bheema Fine Chemicals at Kadechur emerging as the centrepiece of an Rs. 850 crore greenfield expansion across two multi-purpose plants (MPPs).

Phase I of the project, involving Rs. 500 crore of investment, has already been commissioned in 3QFY26 and is rapidly ramping up, with utilisation expected to reach ~85–90% by April 2026. Phase II, pegged at Rs. 350 crore, is currently under construction, with civil works nearing completion and commissioning targeted for 1HFY28E after a 9–12 month engineering and execution cycle.

The new facility marks a step-change in scale and capability. Built with larger reactors and CDMO-aligned infrastructure, it is designed to match global benchmarks and unlock more than three times the current volume and revenue potential at peak utilisation.

Management expects margin expansion as legacy bottlenecks—smaller reactors and limited scalability—are phased out, alongside stronger backward integration.

Flexibility is a key differentiator. The site has environmental clearance for 32 molecules, expandable to 47, significantly broadening its product basket and reducing concentration risk. This stands in sharp contrast to the legacy setup, where the top three products account for nearly 80% of revenues.

BCIL is also aggressively expanding its pipeline, evaluating molecules such as Cartap, Chlorantraniliprole (CTPR), Diafenthiuron, Tembotrione, Thifluzamide, and Tolfenpyrad, among others. The strategy focuses on deeper backward integration—extending up to base chemicals and key starting materials—to reduce import dependence and improve cost competitiveness versus China.

While the company is exploring CDMO opportunities with multinational players, management expects this segment to remain capped at around 25% of peak revenues, with domestic-focused molecules and integration-led efficiency forming the core growth engine going forward.